Question-and-Answer Session
Operator
[Operator Instructions]. Your first question comes from Glenn Garmont with Broadpoint Capital.
Glenn Garmont – Broadpoint Capital
Blane, you mentioned that the company is going to be announcing some new contract wins in the back half. Can you just elaborate on that a bit? Are these joint pitches? Are these integrated wins? Maybe a little more color on what those contracts are going to look like, and then, Dave, I’m sorry I missed as you were providing some color on the earnings progression. The third quarter, was that expected to be flat sequentially or flat year or year? I missed that.
Blane Walter
Glenn, commenting on the new wins that we specifically identified, there were seven that we highlighted. Two are new on-boarding relationship and five are new teams in general, our traditional teams, that we’ll be rolling out over the second half of the year. I’ll let Dave comment a little bit on timing, and then have Dave comment on your second question.
David Bassin
With regard to those new wins, they will be rolling out during the second half of the year, with the majority of the impact from a revenue and profitability standpoint occurring in Q4, from a size and scope similar to the other on-boarding programs. We would expect an initial launch of those teams and then with regard to the dedicated teams, they vary in size from small to mid size. On the second part of your question, the earnings expectation for the third quarter, that we mentioned would be relatively flat with comparable to Q2 of this year.
Operator
Your next question comes from Dave Windley with Jefferies & Company.
Dave Windley – Jefferies & Company
I wanted to drill into the new wins a little bit myself. Blane, you commented about some of the challenges that you’re facing being driven by lack of FDA approvals and some cutbacks in budgets. These new wins, I think in your prepared remarks, you characterized them as verbal awards. How confident are you that these are actually going to come through and ramp up in the back half of the year, and to what extent are those new teams, I know the answer on the on-boarding teams, but to what extent are those new teams contingent upon some type of either approval or licensing activity or something like that?
Blane Walter
Let me break that down into a couple of pieces. First of all, I talked about the FDA non-approvals. That is really specific to our communications division. Second quarter was a good quarter; however, it was a quarter that the communications division received some negative news on products that frankly we had expected to be approved, and they were products that over the course of the year we were ramping up for and then ramped down for. However, the total growth has been more than made up by the exceptional strong performance that we’re seeing out of the commercial business. We expect that we’re in a position to reconfirm our revenue growth targets that we’d set out earlier this year, but we have obviously a different mix shift on the margin side. As it relates to specifics as to where we are on those contracts, maybe Terry you want to comment on that?
- To read the full transcript on Seeking Alpha, click here »
